Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Nov;24(1):1909-1926.
doi: 10.1080/10717544.2017.1410256.

Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy

Shan-Shan Qi  1   2 , Jia-Hui Sun  1 , Hao-Han Yu  3 , Shu-Qin Yu  1
Affiliations
Review

Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy

Shan-Shan Qi et al. Drug Deliv. 2017 Nov.

Abstract

To achieve superior therapeutic efficacy, the combination chemotherapy using two or more anticancer drugs in clinical practice has been generally accepted as a feasible strategy. On account of the concept of combination chemotherapy, co-delivery of anticancer drugs with nanotechnology gradually becomes a desired strategy and one of the research frontiers on modern drug delivery. In recent years, nano drug co-delivery system (NDCDS), which loads at least two anticancer drugs with different physicochemical and pharmacological properties into a combination delivery system, has achieved rapid development. NDCDS synergistically inhibited the growth of the tumor compared with the free drugs. In this review, we highlighted the current state of co-delivery nanoparticles and the most commonly used nanomaterial, discussed challenges and strategies, and prospect future development.

Keywords: Combination chemotherapy; drug delivery materials; multidrug resistance (MDR); nano drug co-delivery system (NDCDS); targeting nanoparticles.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the authors.

Figures

Figure 1.
Figure 1.
Schematic illustration of NDCDS models: the physicochemical and pharmaceutical properties, pharmacodynamic, and pharmacokinetic profiles.
Figure 2.
Figure 2.
Mechanisms illustration of NDCDS reversing MDR: the potential process of from blood to pharmacological target.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abouzeid AH, Patel NR, Sarisozen C, Torchilin VP. (2014a). Transferrin-targeted polymeric micelles co-loaded with curcumin and paclitaxel: efficient killing of paclitaxel-resistant cancer cells. Pharm Res 31:1938–45. - PMC - PubMed
    1. Abouzeid AH, Patel NR, Torchilin VP. (2014b). Polyethylene glycol-phosphatidylethanolamine (PEG-PE)/vitamin E micelles for co-delivery of paclitaxel and curcumin to overcome multi-drug resistance in ovarian cancer. Int J Pharm 464:178. - PMC - PubMed
    1. Ana Catarina Pinto JNM, Simões S. (2011). Combination chemotherapy in cancer: principles, evaluation and drug delivery strategies. In: Ozdemir O, ed. Current cancer treatment – novel beyond conventional approaches. Istanbul: InTech, 693–714.
    1. Bajelan E, Haeri A, Vali AM, et al. . (2012). Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance. J Pharm Pharm Sci 15:568–82. - PubMed
    1. Bonavida B, Khineche S, Huerta-Yepez S, Garbán H. (2006). Therapeutic potential of nitric oxide in cancer. Drug Resist Updat 9:157–73. - PubMed

Substances

Grants and funding

This work received financial support from the National Natural Science Foundation of China (Project no. 81673214), and Project Foundation of the Priority Academic Program Development of Jiangsu Higher Education Institutions.